Galapagos NV (Galapagos NV) Equity-to-Asset

: 0.64 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Galapagos NV's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3,048.6 Mil. Galapagos NV's Total Assets for the quarter that ended in Dec. 2023 was $4,751.8 Mil. Therefore, Galapagos NV's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.64.

The historical rank and industry rank for Galapagos NV's Equity-to-Asset or its related term are showing as below:

GLPGF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47 Med: 0.67 Max: 0.84
Current: 0.64

During the past 13 years, the highest Equity to Asset Ratio of Galapagos NV was 0.84. The lowest was 0.47. And the median was 0.67.

GLPGF's Equity-to-Asset is ranked worse than
51.73% of 1564 companies
in the Biotechnology industry
Industry Median: 0.66 vs GLPGF: 0.64

Galapagos NV Equity-to-Asset Historical Data

The historical data trend for Galapagos NV's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

0.47

0.51

0.53

0.64

Galapagos NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.53	0.55	0.57	0.59	0.64

Competitive Comparison

For the Biotechnology subindustry, Galapagos NV's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galapagos NV Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Galapagos NV's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Equity-to-Asset falls into.

Galapagos NV Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Galapagos NV's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	3048.6	/	4751.795
	=	0.64

Galapagos NV's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	3048.6	/	4751.795
	=	0.64

Galapagos NV (OTCPK:GLPGF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Galapagos NV Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (Galapagos NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (OTCPK:GLPGF) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

GLPG:USA GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.